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BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major burden for the health care system, but the exact costs are
difﬁcult to estimate and there are insufﬁcient data available on past and future time trends of COPD-related costs.
AIMS: The aim of the study was to calculate COPD-related costs in Finland during the years 1996–2006 and estimate future costs for
the years 2007–2030.
METHODS: COPD-related direct and indirect costs in the public health care sector of the whole of Finland during the years
1996–2006 were retrieved from national registers. In addition, we made a mathematical prediction model on COPD costs for the
years 2007–2030 on the basis of population projection and changes in smoking habits.
RESULTS: The total annual COPD-related costs amounted to about 100–110 million Euros in 1996–2006, with no obvious change,
but there was a slight decrease in direct costs and an increase in indirect costs during these years. The estimation model predicted
a 60% increase up to 166 million Euros in COPD-related annual costs by the year 2030. This is caused almost entirely by an increase
in direct health care costs that reﬂect the predicted ageing of the Finnish population, as older age is a signiﬁcant factor that
increases the need for hospitalisation.
CONCLUSIONS: The total annual COPD-related costs in Finland have been stable during the years 1996–2006, but if
management strategies are not changed a signiﬁcant increase in direct costs is expected by the year 2030 due to ageing
of the population.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is highly prevalent
worldwide, and it is estimated to become the third most common
cause of death globally by the year 2020.1 The prevalence of
COPD in the Finnish adult population is about 4–10% depending
on the deﬁnition used.2–4 In two recent population-based studies,
the prevalence of COPD, as deﬁned by post-bronchodilator
ratio of forced expiratory volume in 1 s to forced vital capacity
o0.7, was 9.4% among 21–70-year-old subjects in Northern
Finland2 and 5.9% among 26–74-year-old subjects in Helsinki.4
Of the latter population, 0.6% had severe, 3.0% had moderate
and 2.2% had mild COPD. These ﬁgures are roughly in line
with those published internationally,5 but even higher ﬁgures
have been reported in, e.g., Northern Sweden6 and Denmark.7
Although the age-adjusted prevalence of COPD has not changed
during the last few decades in Finland,3 the overall incidence
and prevalence of COPD may increase due to ageing of the
population.
COPD is a major disease in economic terms as well. The direct
annual health care costs of COPD in the European Union are
estimated to be about 23.3 billion Euros.8 A large share of this is
thought to be caused by hospitalisations due to acute exacerba-
tions of COPD. Comorbidities related to COPD further increase the
total costs, but their effects are difﬁcult to estimate. As COPD-
related health care costs are associated with the severity of the
disease, early diagnosis and smoking cessation is advocated to
hinder the disease progression1 and thereby hopefully also
decrease health care costs.
New drugs, such as long-acting bronchodilators, have been
introduced for the treatment of COPD during the last two
decades. The use of these drugs increases the direct medicinal
costs of COPD. However, as the drugs improve health status in
subjects with COPD,1 they might in turn decrease the costs caused
by outpatient visits. Most importantly, the drugs are also shown to
decrease the risk for acute exacerbations and hospitalisations,1
and this might be an important factor in decreasing the total
COPD-related costs. Further, changes in treatment protocols of
hospitalised patients towards shorter in-hospital periods are likely
to affect the total costs. Unfortunately, it is not well known how
these factors have changed the COPD-related health care costs on
a nationwide basis. The Finnish health care system with its
comprehensive statistics offers a good opportunity for estimating
COPD-related costs and the effects of the above-mentioned
parameters on the costs.
The aims of the current study were to study the change in
total national COPD-related costs in Finland during the years
1996–2006 and estimate the future annual COPD-related costs in
Finland for the years 2007–2030. The study was conducted by the
Nordic Health Care Group and it was funded by Boehringer-
Ingelheim Finland.
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MATERIALS AND METHODS
Annual costs 1996–2006
The annual costs of COPD during the years 1996–2006 were calculated
using health care registers and statistics covering the whole population in
Finland (5.1 million people in 1996 and 5.3 million in 2006). The direct costs
of COPD were regarded as costs caused by hospitalisations due to COPD,
outpatient visits due to COPD and the costs of COPD medication. The
indirect costs of COPD included sickness allowances and disability
pensions due to COPD. In contrast to some other studies, we did not
ﬁrst identify a certain population of subjects with COPD and then add up
all their health care costs from registers using their personal identity codes.
Instead, we utilised national registers of different health care services or
social beneﬁts and identiﬁed all such events where COPD was labelled as
the cause of that service/beneﬁt.
Direct costs
Costs of hospitalisations and outpatient visits: The core of the Finnish
health care system is public health care, which consists of primary (both
outpatients and inpatients) and secondary health care (both outpatients
and inpatients) services. All outpatient visits, hospitalisations and medical
procedures in secondary public health care and hospitalisations in primary
health care are registered with the related ICD-10 diagnosis code by the
National Institute for Health and Welfare.9 The costs for private health care
or occupational health care systems were excluded, as no register data of
COPD patients treated in those sectors could be obtained.
We included in the analysis all outpatient visits, days in hospital and
medical procedures with ICD-10 diagnostic codes J43 (emphysema) or J44
(COPD) as the primary cause. The unit costs in 2006 for a day in hospital
and for an outpatient visit were obtained from the National Institute for
Health and Welfare10 and are given in Table 1. The pricing of medical
procedures was based on average DRG prices quoted by hospitals.10 The
unit costs for other years were derived from these by using inﬂation
corrections with price index on public expenditure provided by Statistics
Finland.11
Medication costs: In Finland, all drugs bought from pharmacies are
registered with the buyers' identity to the Finnish Statistics on Medicines,12
but this register does not include the diagnostic codes. However, patients
with severe enough asthma or COPD gain a special reimbursement for
their medication. If a person entitled to such a reimbursement buys
medication, data on this can be retrieved from the registers. Subjects with
asthma and COPD are not separated in this register but are considered a
single group of patients with obstructive pulmonary diseases. To avoid
including medication used to treat asthma, we deﬁned COPD-related
drugs as drugs for the treatment of respiratory diseases bought by persons
who were entitled to a special reimbursement for obstructive pulmonary
diseases and who also used inhaled anticholinergics (these were only
seldom used to treat asthma in Finland during 1996–2006). The costs for
these COPD-related drugs were gained from the Finnish Statistics on
Medicines.12
Indirect costs. Indirect costs of COPD, i.e., the loss of productivity due to
illness, were calculated on the basis of sickness allowances and disability
pensions due to COPD. In Finland, all sickness allowances with the ICD-10
code of the cause are registered by the Social Insurance Institution,13 and
disability pensions with the ICD-10 code of the cause are registered by the
Finnish Centre for Pensions.14 The data we retrieved from the registers
included the number of days on sickness allowance and the number of
subjects on disability pension due to COPD (J33 or J44). These were then
transformed into lost man-years, and the costs for these were calculated
using the unit cost, quoted by the National Institute for Health and Welfare,
of 24,600€ per year in 2006.10
Mortality caused by COPD was not included in the calculations of loss of
productivity, as most COPD-related deaths occur at older age when the
subject has already retired. We excluded also the following indirect costs
that are difﬁcult to deﬁne and calculate: impaired productivity at work
while still present (presenteism),15 work outside of paid work, care-giving
by family members and immaterial costs, the loss of productivity or
decrease in retirement pensions due to mortality caused by COPD.
Estimated annual costs for 2007–2030
The estimation model was built on an assumption that smoking history,
age and sex are the major factors determining (the risk of COPD and)
COPD-related costs. In this model, we did not try to estimate the actual
number of subjects with COPD, but our model assumes that the fractions
of active smokers and recent quitters that have COPD and cause
COPD-related costs remain the same in the future.
First, we assessed the total COPD-related costs in 2006, as described in
the ﬁrst part of the manuscript, separately in each age group (5-year
intervals) in both sexes. Second, we retrieved the percentages of active
smokers and recent quitters (during the previous 10 years) separately in
each corresponding age group and both sexes from the Tobacco Statistics
in Finland.16 We then calculated in each age group and sex ‘smoking
standardised COPD costs’ in 2006 by dividing the actual COPD-related
costs in 2006 by the number of active smokers and recent quitters with the
following weighing factors: 1 for active smokers and those ex-smokers who
had quit 1–3 years ago; 0.75 for ex-smokers who had quit 3–5 years ago;
and 0.5 for ex-smokers who had quit 5–10 years ago.
To calculate the COPD-related costs in each age group and gender in the
years 2007–2030, we needed to calculate the numbers of smoking subjects
and recent quitters in each age group and gender in each of the years. We
began by calculating the percentages of active smokers and recent
quitters in each age group and sex for each year from 2007 to 2030 by
assuming that the fractions of active smokers and recent quitters
(1–3 years ago, 3–5 years ago and 5–10 years ago) continue to change
at the same rate they have changed during the years 1996–2006 in Finland
based on the Tobacco Statistics.16 We then multiplied these percentages of
smokers and recent quitters by the estimated numbers of subjects in each
age group and sex retrieved from the population projection in Finland17 to
get the actual numbers of smokers and recent quitters in each group and
year. Finally, these numbers of active smokers and recent quitters in each
age group, sex and year were multiplied by the ‘smoking standardised
COPD costs’ in 2006 using the same weighing factors for smokers and
quitters as mentioned above. These total annual COPD-related costs
during the years 2007–2030 were then corrected by an assumed annual
inﬂation factor of 2%.
RESULTS
Annual costs 1996–2006
The numbers of outpatient visits, days in hospital, days on sickness
allowance and sickness pensions retrieved from the registers are
given in Table 2, both in absolute values and also per 100,000
inhabitants. There was a 17% increase in primary care hospital
Table 1. The unit costs of health care services and cost for lost
man-years due to sickness allowance or disability pension obtained
from the National Institute for Health and Welfare in the year 2006
Unit cost, €
Days in hospital in primary care 142
Days in hospital in secondary care 590
Secondary care outpatient visits 200
Lost man-year due to sickness allowance or
disability pension
24,600
Table 2. Numbers of hospitalisation days, outpatient visits, days on
sickness allowance and subjects on disability pension retrieved from
registers in 1996 and 2006
1996 2006
Population in Finland 5,132,320 5,276,955
Days in hospital in primary care 58,986 (1,149) 69,021 (1,308)
Days in hospital in secondary care 68,231 (1,329) 32,446 (615)
Secondary care outpatient visits 22,179 (432) 20,115 (381)
Days on sickness allowance due
to COPD
59,104 (1,152) 64,354 (1,220)
Subjects on disability pension due
to COPD
1,928 (38) 1,844 (35)
The numbers are in total values in Finland and per 100,000 inhabitants in
parenthesis.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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days but a simultaneous 52% decrease in more expensive
secondary care hospital days. Changes in outpatient visits, days
on sickness allowances and persons on disability pensions were
not marked.
The time trends of key COPD-related costs in the period 1996–
2006 are presented in Figure 1, and the exact numbers in total and
per 100,000 inhabitants in the years 1996 and 2006 are given in
Table 3. The annual total COPD-related costs in Finland varied
between 101 and 110 million Euros during the period 1996–2006
and there was no obvious change (Figure 1). However, there was a
slight decrease in direct costs from 63.6 to 56.3 million Euros and a
similar slight increase in indirect costs from 46.5 to 51.4 million
Euros during these years (Table 3). The decrease in direct costs
was caused by reduced number of days in hospital in secondary
care causing a marked decrease in costs of about 16 million Euros.
However, this was somewhat outweighed by a simultaneous
increase in medication costs of about 6 million Euros and by
smaller increases in other direct costs. The rise in indirect costs
was caused mainly by increase in unit costs for lost productivity, as
there were no marked changes in the days on sickness leave or
subjects on disability pension (Table 2).
Estimated annual costs for 2007–2030
On the basis of our calculations, the annual COPD-related costs in
Finland will increase by about 60% during the years 2007–2030
from 107 to 166 million Euros (Figure 2). The main reason for this
increase is the signiﬁcant ageing of the Finnish population in the
years to come, as both the prevalence of COPD and especially
the use of health care services increase with ageing. Even the
decreasing trend in the fraction of smokers does not seem to
balance out the effect of ageing. This ageing-related increase in
total costs is caused almost entirely by increasing direct costs
(hospitalisations, outpatient visits and medical costs). The indirect
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Figure 1. Total COPD-related costs in Finland during the years 1996–2006 retrieved from national registers and divided into major
components. COPD, chronic obstructive pulmonary disease.
Table 3. Direct and indirect costs of COPD in the whole population of Finland in the years 1996 and 2006, both in absolute values and per 100,000
inhabitants
1996 2006
Total costs (€) Costs per 100,000 inhabitants (€) Total costs (€) Costs per 100,000 inhabitants (€)
Outpatient visit costs, SHC 3,890,214 75,798 4,023,000 76,237
Hospitalisation costs, SHC 35,321,979 688,226 19,154,939 362,992
Hospitalisation costs, PHC 7,371,664 143,632 9,835,330 186,383
Costs of medication 17,046,441 332,139 23,268,935 440,954
Total direct costs 63,630,298 1,239,796 56,282,204 1,066,566
Costs of sickness allowances 4,897,021 95,415 6,074,400 115,112
Costs of disability pensions 41,592,319 810,400 45,348,966 859,378
Total indirect costs 46,489,340 905,815 51,423,366 974,489
Total costs 110,119,638 2,145,611 107,705,570 2,041,055
Abbreviations: COPD, chronic obstructive pulmonary disease; PHC, primary health care; SHC, secondary health care.
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increased morbidity at older age, when already retired from work,
does not affect the productivity.
DISCUSSION
Main ﬁndings
The main ﬁndings of the study were that the total COPD-related
costs in Finland were stable at about 100 million Euros annually
during the years 1996–2006, but due to the forthcoming ageing of
the population the annual costs are estimated to increase by
about 60% by the year 2030.
Interpretation of ﬁndings in relation to previously published work
Cost-of-illness studies can be divided into two types: top-down
studies, like this one, estimating total costs on the basis of the
register data on a national level, and bottom-up studies that
follow individual patients recording all their costs and then
extrapolating these to national level by taking into account
disease prevalence. Top-down studies generally include a limited
number of different costs and they exclude underdiagnosing,
whereas bottom-up studies include costs of comorbidities as well,
and the prediction of total national costs is dependent on the
accuracy of prevalence estimates. These issues must be taken into
consideration when comparing different studies.
A Swedish top-down study18 estimated that in 1991 the total
COPD-related cost in Sweden was about 3.2 million Euros per
100,000 inhabitants (2,784 million SEK (Swedish Krona) in total,
1 €≈10 SEK and Sweden’s population was about 8.6 million in
1991). This estimate is somewhat higher than our estimate of total
COPD-related costs in Finland in the year 1996 (2.1 million Euros
per 100,000 inhabitants). This difference may be, in part, explained
by the fact that the Swedish study also estimated mortality-related
costs and by the fact that the mean length of hospitalisation may
have decreased already between 1991 and 1996 in both the
countries. A more recent study from Sweden19 gave a much
higher estimate of the total COPD-related costs, totalling 15.7
million Euros per 100,000 inhabitants (1.46 billion Euros in total;
Swedish population 9.3 million in 2010), but this may be explained
by the bottom-up design of the study. In Denmark in the year
2002, COPD-related costs were estimated by a top-down study20
to be 4.7 million Euros per 100,000 inhabitants (256 million Euros
in total; Danish population 5.4 million in 2002), which is more in
the same range with our study and the top-down study from
Sweden.
A previous study in Finland reported that the annual costs of
COPD were 194 million Euros.21 The difference from our result
(about 100 million) may be explained by the broader spectrum of
diagnostic labels included in the previous study (also J40–J42
(chronic bronchitis) and J47 (bronchiectasis)) in retrieving health
care utilisation data from the registers. Furthermore, the previous
study calculated hospital treatment to be caused by COPD even if
COPD was not the primary diagnosis, whereas the current study
included only those treatment periods in which COPD was
labelled as the primary cause of hospitalisation. Including only
treatment periods with COPD as the primary diagnosis may
underestimate the costs caused by acute exacerbations of COPD,
as some of these periods may be labelled with a diagnosis of
acute bronchitis or pneumonia. On the other hand, considering
that all treatment periods are caused by COPD, where COPD is
included in the list of the patient’s diagnoses, surely causes
overestimation of COPD-related costs, as these subjects are
treated for other diseases as well. Such differences between
studies make it difﬁcult to compare the results.
A previous study22 has estimated that COPD-related costs in
Finland have decreased by 88% from 1997 to 2007. However, the
costs at different time points were retrieved from different studies
with considerable differences in the calculation methods used.
This severely undermines the reliability of the stated huge
decrease in COPD-related costs. To our knowledge, the current
study is the ﬁrst using the same methods consistently in assessing
the annual COPD-related costs in Finland during a wide range of
years. We found that there was no obvious change in total COPD-
related costs during the period 1996–2006.
Although the total COPD-related costs were stable during the
years 1996–2006, there was a decrease in the direct costs and a
corresponding increase in the indirect costs. The direct costs
decreased mainly due to a decrease in the number of in-hospital
days. This reﬂects changes in clinical practice regarding the
treatment of acute exacerbations of COPD. The number of hospital
treatment periods was about the same in 1996 and 2006, but the
mean length of the treatment periods decreased, which also
decreased the total number of treatment days. Our ﬁnding is in
line with a recent report from Sweden19 in which costs of

































































Figure 2. Predicted total COPD-related costs in Finland during the years 2007–2030 divided into direct (open bars) and indirect (hatched bars)
costs. COPD, chronic obstructive pulmonary disease.
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and 2010 but there was a simultaneous increase in
medication costs.
There are not many prediction studies of future COPD costs
available internationally, but a recent study23 estimated a 53%
increase in national COPD costs in the United States from 32.1
billion dollars in 2010 to 49 billion dollars by the year 2020. This is
in line with our estimate of a 60% increase in COPD costs by the
year 2030 in Finland.
Strengths and limitations of this study
This study is based on national registers covering the public health
care system in the whole of Finland and gives a reliable estimate
on the true costs of COPD. However, our estimate of total costs is
likely a conservative one because of several reasons. First, the
exact reason and primary diagnosis for hospitalisation of a subject
with COPD and many comorbidities is not always straightforward,
and some exacerbations of COPD are certainly treated under other
diagnoses, which may lead to underestimation of hospitalisation
costs. Second, outpatient visits in private health care systems or in
primary public health care could not be included because of lack
of reliable registers. However, this is probably not a signiﬁcant
issue, as the costs of outpatient visits are small when compared
with hospitalisations and indirect costs, and the number of visits
of elderly people in private health care is very small. Third, not all
patients with mild or moderate COPD have a special reimburse-
ment for medication, and the medication costs of subjects without
this reimbursement are not included in this analysis. As
medication costs are higher in subjects with severe COPD, this
may not be a marked ﬂaw but leads to underestimation in any
case. Furthermore, the indirect costs are always difﬁcult to deﬁne
and calculate, and we did not include, e.g., the possibility that
mortality due to COPD might decrease the expenses of retirement
pensions due to earlier death of subjects with COPD.
Our estimate of future costs assumes that the effectiveness of
the health care system and the age-adjusted need for hospitalisa-
tion will be at the current level in the future also. However, if new
treatments emerge that signiﬁcantly decrease the need for
hospitalisation or shorten hospitalisation periods, the increase in
future costs might be smaller than estimated here. Our model on
the future prevalence of COPD also assumed that the age-
adjusted proportion of smokers in the population will continue to
decrease at the same rate as it has in previous years. If the
smoking trends deviate from the assumption either up- or
downwards, this might decrease the liability of our estimate on
the prevalence of COPD. However, there is a considerable latency
period between changes in smoking habits and changes in COPD
prevalence, and our time period for the estimate is only 24 years.
Therefore, the accuracy in predicting future smoking habits is not
that important for the time period of 24 years, but it would be
much more pivotal for longer time periods.
A weakness of the current study, as with all prediction models,
is that in predicting future COPD-related costs we needed to
estimate several parameters on the basis of their time trends in
the past. However, while doing this we tried to be as realistic, or
even conservative, as possible.
Implications for future research, policy and practice
In the past, the prevalence of COPD has been on the rise due to
ageing of the population, and the medicine costs have also risen
as new drugs have become available. However, these factors
increasing the costs have been balanced out by increased
efﬁciency of the health care system that has decreased the length
of in-hospital periods. The Finnish population will be ageing
much more rapidly during the next 20 years than during the years
1996–2006. The number of patients with COPD will increase
especially in the older age groups, in which also the need
for hospital treatment is the greatest. This is why there will be
ageing-related increase in total COPD-related costs in the future,
although this did not take place in the past. As the older age
groups have already retired, the higher prevalence of COPD
among these subjects does not cause an increase in indirect costs
that are related to loss of productivity.
The ageing-related increase in COPD costs should be taken into
account in Finland when planning the national health care
strategy. The results can be expanded to other western countries
with similar smoking habits and ageing of the population. As the
streamlining of the health care system in treating exacerbations
has already taken place, this is likely not a signiﬁcant option in
reducing the costs anymore. Instead, focus should be on smoking
policy to decrease age-adjusted COPD incidence and on the
management of stable COPD to decrease the risk for
exacerbations.
Conclusions
In conclusion, the annual costs of COPD in Finland have been
stable during the years 1996–2006, but the costs are estimated to
increase by 60% until the year 2030 mainly due to ageing of the
population. A strict smoking policy is needed to decrease COPD-
related morbidity and the future rise in costs, and possible new
treatment options need to be assessed in terms of cost
effectiveness as well.
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